ArticleFrontiers in medicine2026
Hemodynamic effects of red blood cell transfusion in patients with hemato-oncologic diseases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The hemodynamic effects of red blood cell (RBC) transfusion in patients with hemato-oncologic diseases can be adverse. We measured acute hemodynamic changes with a novel non-invasive monitoring device. Methods: Twenty-six patients (9 female, 17 male; median age 73) with hematological malignancies or solid tumors were included. Peripheral and central hemodynamics were assessed before and after RBC transfusion using the VascAssist2.0 device. Results: Baseline hemoglobin was 7.8 g/dL (range 6.2-8.7). Post-transfusion, significant hemodynamic changes were observed: heart rate decreased from 81 to 74 bpm ( Conclusion: RBC transfusion in patients with hemato-oncologic diseases resulted in significant increases in central and peripheral blood pressures and a reduction in heart rate in our pilot study. Trends toward improved blood rheology and vascular function were observed, though not statistically significant. While these immediate hemodynamic effects appear beneficial, further research is needed to determine long-term outcomes, especially for patients requiring frequent transfusions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.